Arch Scientists to Present at ESF-LFUI Conference in Austria
TORONTO, ONTARIO--(Marketwire - May 24, 2011) - Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists Randall Irvin and Elisabeth Davis will be presenting new data at a conference titled "Charge Transfer in Biosystems" sponsored by the European Science Foundation ("ESF") and University of Innsbruck ("LFUI") held July 17-22, 2011 at the Universitätszentrum Obergurgl in Tirol, Austria.
At the ESF conference, Professor Irvin will present an oral presentation titled "Spontaneous Modulation of the Electronic State of Stainless Steel via a Novel Synthetic Bio-metallic Interface" which will highlight new bioelectrical properties relating to Arch Biophysics' core technology (binding proprietary peptides to non-biological solid surfaces). Ms. Davis will be presenting a related poster at the conference
This new data is in addition to the findings disclosed in the recent article published by Davis, Li and Irvin in the journal Biomaterials showing that Arch Biophysics' novel synthetic peptides increase the hardness and resistance to corrosion of stainless steel.
The European Science Foundation was established in Strasbourg in 1974 and today has a membership of 78 Member Organizations, including research councils, research funding organizations, research performing organizations, academies and learned societies in 30 countries. Members include the Medical Research Council (U.K), the German Research Foundation and the French National Research Agency. For more information about ESF please visit www.esf.org.
Arch Biophysics Ltd is an Alberta corporation wholly owned by Arch Biopartners. Arch Biophysics' technology development program has created novel synthetic peptides that bind to solid surfaces such as steel, titanium various plastics and glass. Arch and its scientists believe that these proprietary peptides are unique. Experimental results have shown novel physical, chemical and bioelectrical properties that have many potential commercial applications in the medical, dental and industrial sectors.
About Arch Biopartners
Arch Biopartners is a portfolio based technology development company focused on developing early stage proprietary technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.